I knew I should have read the abstract book for ASCO

Abel Pharmboy shows why I shouldn’t have left my American Society of Clinical Oncology (ASCO) proceedings abstract sit on my desk unread for a week.

Damn. Talk about blowing an opportunity. Of course, given that I don’t own any pharmaceutical stocks (making me a rather poor “tool of big pharma” indeed), it doesn’t matter.